You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Aminopiperidines as novel anti influenza agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Influenza A viruses belong to the orthomyxoviridae family with a negative sense segmented RNA genome which can cause seasonal or pandemic flu with high morbidity and significant mortality Vaccination is the most prevalent prophylactic means for controlling influenza infections However an effective vaccine usually takes at least months to develop for the circulating strains Furthermore vac ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Monochromatic 222 nm UV light: Development of a safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission

    SBC: EDEN PARK ILLUMINATION, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistant bacteria such as MRSA and airborne transmitted microbes such as influenza and TB together present major health issues both in the developed and the developing world with major health care and economic consequences Recent research from Columbia University Medical Center demonstrated that single wavelength far UVC photons can kill bacteria a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A chimeric protein for the selective expansion of regulatory T cells

    SBC: Sahane Biotech, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Type diabetes T D is a chronic disease caused by the autoimmune destruction of the insulin producing beta cells in the pancreas Current treatment options for T D are severely limited All patients diagnosed with T DM are placed on life long insulin therapy and the current standard of care for adult patients with T DM is intensive diabetes therapy to avoid ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Monitored Breathing Awareness Therapy for Insomnia Disorder in Older Adults

    SBC: ADVANCED MEDICAL ELECTRONICS CORPORATION            Topic: NIA

    DESCRIPTION provided by applicant Insomnia of sufficient clinical severity to meet diagnostic criteria is present in approximately of older adults nearly million individuals n the US alone If left untreated it can lead to increased rates of depression cognitive impairment and cardiovascular disease Treatment relies on pharmacotherapy such as sedative hypnotic therapy which is ass ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Developing a method to increase HIV testing among YMSM

    SBC: RESILIENT GAMES STUDIO, LLC            Topic: NICHD

    DESCRIPTION provided by applicant Adolescents are particularly vulnerable to HIV and account for one quarter of all new infections each year Most new infections among adolescents occur among young men who have sex with men YMSM Transmission of HIV can be virtually eliminated by treatment but testing rates are low and a significant proportion of YMSM are unaware of their HIV status P ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression

    SBC: Norfolk Medical Products, INC.            Topic: NIDDK

    DESCRIPTION provided by applicant The Cell SafeTM is a fundamentally new approach in replacement of dysfunctional insulin producing cells in patients with diabetes by transplantation of new islets in a three dimensional scaffold embedded in a highly compatible bioengineered perfusion system that continuously supplies tissue fluid blood ultrafiltrate so that the cells ae protected from immun ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Medical Sensor Applications of Tunnel Magnetoresistance TMR

    SBC: Koronis Biomedical Technologies Corp.            Topic: NIDCD

    DESCRIPTION provided by applicant Koronis Biomedical Technologies KBT proposes to develop a novel omnidirectional low power miniaturized hearing aid telecoil replacement module TCRM based on tunneling magnetoresistance TMR technology It has been reported that million Americans have hearing loss Hearing loss affects in Americans and in households Modern telecoils assist ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Aminomethyl benzamides as novel anti Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government